Managing heart failure requires a holistic approach: as well as optimal medical treatment, patients and their families need to have a sufficient understanding of the condition. There also needs to be a service to deliver this care. Heart failure affects about 0.5% of the population, depending on the age of the population, so each general practice has a manageable number of patients. However, the expertise and confidence needed to deliver optimal care to heart failure patients and their families are not widely held in primary care. There is largely a reliance on secondary care to provide community services, led by consultants and delivered by specialist nurses. Within this system patients are usually well served, but sometimes patients fall between the community service and general practice. In Central Manchester there is no community heart failure service. About one in five patients with heart failure were being admitted each year, indicating that heart failure management in the community needed to improve.
The new oral anticoagulants, and their use in stroke prevention
We have three new licensed anticoagulant agents–dabigatran, rivaroxaban and apixaban. Their use for stroke prevention in AF is discussed: primary care is central to their utilisation.
Keeping the blood flowing: new agents to prevent and treat thrombosis
We live in exciting times with the development of several new oral anticoagulant agents, including the recent approval of the direct thrombin inhibitor dabigatran for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). Dabigatran, an oral agent with fixed dosing, is an attractive alternative to warfarin which has recently been made available in the UK. What are the implications for UK primary care? Many patients with AF receive substandard anticoagulation and are therefore at risk of stroke. Evidence for its efficacy and its potential place in clinical practice is reviewed.
Introducing the new national strategy for CVD
As many will know, the Secretary of State for Health, Andrew Lansley, announced last December that the government would be developing a new strategy for cardiovascular disease under the direction of Sir Bruce Keogh (NHS Medical Director). As part of this work two Interim National Clinical Directors have been seconded to the Department of Health: me (Professor Huon Gray, University Hospital of Southampton) for Cardiovascular Disease and Dr Damian Jenkinson (Royal Bournemouth Hospital) for Stroke. Both are part-time secondments and together cover the work previously overseen by Professor Sir Roger Boyle, before his retirement last summer.
Heart rate control in people with heart failure: education may improve outcomes
There is emerging evidence that heart rate control is an important element in the management of people with heart failure. The major beta-blocker trials have shown improved mortality and reduced hospitalisation when patients with impaired left ventricular (LV) function are managed with optimal doses. In a meta-analysis of these trials, McAlister et al. have shown a correlation between heart rate control and improved outcomes.1 Beta-blockers may have other actions apart from heart rate control; for instance, they may be anti-arrhythmic or have some other mechanisms for their action. Ivabradine, whose only function is heart rate control, has also shown a reduction in hospitalisation for heart failure.2 Heart rate is additionally an indicator of optimal beta-blockade3, and so may be a proxy for optimal medical treatment.
Recognising stroke and transient ischaemic attack – the role of primary care
Stroke is the third commonest cause of adult death and the leading cause of complex disability in the UK. This article will discuss the importance of the early recognition of stroke and transient ischaemic attack and the role of primary care staff in implementing national guidelines. Practical case study examples are included.
How to manage hyperkalaemia, a life-threatening arrhythmia
Hyperkalaemia is a common electrolyte disorder which, when severe, can cause lifethreatening cardiac arrhythmias and paralysis of the respiratory muscles. It is therefore crucial for clinicians to have a clear understanding of its management. Hyperkalaemia is usually caused by a combination of factors, but renal impairment and drugs are often implicated. The rising prevalence of chronic kidney disease and increasing use of medications that interact with the renin-angiotensin-aldosterone system have resulted in a sharp rise in the prevalence of hyperkalaemia.
Improving the management of cardiovascular disease during pregnancy
It is exceedingly uncommon for a woman in the UK to die during pregnancy, with maternal mortality in the region of one death per 10,000 maternities1. Although there have been very significant improvements in antenatal care, such as a marked reduction in the number of deaths due to thromboembolic disease, other areas are trailing behind. One such area is cardiac disease – now the leading cause of maternal death in the UK. These relatively rare deaths also mask the much larger issues of maternal, fetal and perinatal morbidity. The most recent Confidential Enquiries into Maternal Death and the new European Society of Cardiology guidelines summarised in this issue of the PCCJ highlight the major clinical issues and attempt to provide consensus opinion regarding optimal care in what is a relatively evidence-sparse field.
Choosing the NTproBNP cut off for use as part of a community heart failure care pathway
Echocardiography (ECHO) is the “gold standard” test in the diagnosis of heart failure. Brain natriuretic peptide (BNP) can be helpful to rule outpatients who do not require ECHO. This study used an elevated level of Nterminal prohormone BNP (NT-proBNP) as a criterion for referral to a new community heart failure clinic. Results showed that NT-proBNP could be a useful test in the management of heart failure. The researchers propose to institute age- and sex-related cut-offs to refine its place in the patient care pathway.
How can we avoid a stroke crisis?
A report from a multidisciplinary alliance has made a compelling case for a coordinated planin Europe to reduce the health, social and economic burdens of stroke related to atrialfibrillation (AF). The group comprises eminent cardiologists, neurologists, a healtheconomists, hospital pharmacists, a haematologist and representatives from patientorganisations.How Can We Avoid a Stroke Crisis? has been endorsed by 17 medical and patientorganisations, including the European Primary Care Cardiovascular Society. Its aim is tohighlight to European policy makers the need to achieve earlier diagnosis and bettermanagement of AF across Europe, with the ultimate goal of reducing the risk of stroke inpatients with AF. The key points summarised in the report are shown in table 1.
Atrial Fibrillation In Primary care: Bringing practice closer to guidelines – a tool for primary care physicians
In the last few years we have witnessed a number of advances in the management of atrial fibrillation (AF). While these have created valuable opportunities to improve patient outcomes, we need to ensure physicians have the right support to deliver the most appropriate care. The AF AWARE (Atrial Fibrillation AWareness And Risk Education) campaign, working with a panel of AF experts, has developed the Atrial Fibrillation in Primary care (AFIP) tool – a ‘go to’ resource for primary care physicians, to help with the identification and management of AF, in line with the latest published guidelines. This article provides some background to the need for such a tool, and an outline of its content.
CT coronary calcium scoring: improving cardiac risk stratification
We describe the technique, application, risks and benefits of computed tomography (CT) coronary calcium scoring in relation to how it could be used in primary care to help produce an individualised cardiac risk assessment.
